JP2015508816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508816A5 JP2015508816A5 JP2014559875A JP2014559875A JP2015508816A5 JP 2015508816 A5 JP2015508816 A5 JP 2015508816A5 JP 2014559875 A JP2014559875 A JP 2014559875A JP 2014559875 A JP2014559875 A JP 2014559875A JP 2015508816 A5 JP2015508816 A5 JP 2015508816A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- therapeutic
- antigen
- agent
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 45
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 35
- 239000000556 agonist Substances 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 108090000695 Cytokines Proteins 0.000 claims description 26
- 102000004127 Cytokines Human genes 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 20
- 108091008874 T cell receptors Proteins 0.000 claims description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 18
- 238000005829 trimerization reaction Methods 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 230000009401 metastasis Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 238000002619 cancer immunotherapy Methods 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 6
- 102000004473 OX40 Ligand Human genes 0.000 claims description 6
- 108010042215 OX40 Ligand Proteins 0.000 claims description 6
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 6
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 5
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 claims description 4
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 108700025316 aldesleukin Proteins 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- -1 NHS-EMD 521873 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 229960005310 aldesleukin Drugs 0.000 claims description 2
- 230000005904 anticancer immunity Effects 0.000 claims description 2
- 230000008512 biological response Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 57
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/027496 WO2013130102A2 (en) | 2012-03-02 | 2012-03-02 | Dual ox40 agonist/il-2 cancer therapy methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015508816A JP2015508816A (ja) | 2015-03-23 |
| JP2015508816A5 true JP2015508816A5 (enExample) | 2015-07-16 |
Family
ID=49083426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559875A Pending JP2015508816A (ja) | 2012-03-02 | 2012-03-02 | Ｏｘ４０アゴニスト／ｉｌ−２二重癌治療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150157710A1 (enExample) |
| EP (1) | EP2819693A4 (enExample) |
| JP (1) | JP2015508816A (enExample) |
| AU (1) | AU2012371610A1 (enExample) |
| CA (1) | CA2865899A1 (enExample) |
| HK (1) | HK1205691A1 (enExample) |
| WO (1) | WO2013130102A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| CA2935878C (en) * | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| SG10201808746QA (en) | 2014-04-03 | 2018-11-29 | Augusta University Research Institute Inc | Methods for enhancing the efficacy of a tumor-directed immune response |
| CN106456734A (zh) * | 2014-05-29 | 2017-02-22 | 免疫医疗有限责任公司 | Ox40l融合蛋白及其用途 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| DK3209778T3 (da) | 2014-10-24 | 2019-05-27 | Astrazeneca | Kombination |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| CA3043597A1 (en) * | 2016-11-10 | 2018-05-17 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| WO2020176771A1 (en) | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
| EP4037693A1 (en) | 2019-09-30 | 2022-08-10 | Astrazeneca AB | Combination treatment for cancer |
| CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
| CN119896729A (zh) * | 2023-10-26 | 2025-04-29 | 南开大学 | 靶向髓系细胞进而增强ox40激动剂抗体药效的药物组合物的药物组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20030035790A1 (en) * | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
| US20030040477A1 (en) * | 2002-09-23 | 2003-02-27 | Anthony Montgomery | Methods and compositions for modulating t cell activation and uses thereof |
| JP4035579B2 (ja) * | 2003-12-22 | 2008-01-23 | 北海道ティー・エル・オー株式会社 | 標的化ｔ細胞の製造方法及び医薬 |
| US20110008368A1 (en) * | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| US8629098B2 (en) * | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
-
2012
- 2012-03-02 HK HK15106316.7A patent/HK1205691A1/xx unknown
- 2012-03-02 JP JP2014559875A patent/JP2015508816A/ja active Pending
- 2012-03-02 EP EP12869998.0A patent/EP2819693A4/en not_active Withdrawn
- 2012-03-02 CA CA2865899A patent/CA2865899A1/en not_active Abandoned
- 2012-03-02 US US14/381,785 patent/US20150157710A1/en not_active Abandoned
- 2012-03-02 WO PCT/US2012/027496 patent/WO2013130102A2/en not_active Ceased
- 2012-03-02 AU AU2012371610A patent/AU2012371610A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gatti-Mays et al. | If we build it they will come: targeting the immune response to breast cancer | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Martin-Liberal et al. | The expanding role of immunotherapy | |
| Aspeslagh et al. | Rationale for anti-OX40 cancer immunotherapy | |
| Khalil et al. | Anti-CD40 agonist antibodies: preclinical and clinical experience | |
| Sandin et al. | Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| WO2022115946A1 (en) | Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists | |
| JP2016537340A5 (enExample) | ||
| JP2017537892A5 (enExample) | ||
| JP2022502037A5 (enExample) | ||
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| Ju et al. | Eradication of established renal cell carcinoma by a combination of 5‐fluorouracil and anti‐4‐1BB monoclonal antibody in mice | |
| US20150157710A1 (en) | Dual ox40 agonist/il-2 cancer therapy methods | |
| WO2021068196A1 (en) | Methods of using il-33 protein in treating cancers | |
| JP2018512397A (ja) | 癌治療の有効性を高めるための組成物及び方法 | |
| TWI845626B (zh) | 增進治療癌症功效的il-4/il-13途徑抑制劑 | |
| Liu et al. | Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| KR102578682B1 (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| CN113543809A (zh) | 用于治疗癌症的免疫疗法 | |
| KR20190098995A (ko) | 면역 반응의 조절을 위한 옥사바이사이클로헵탄 | |
| JP2020528449A5 (enExample) | ||
| Redmond | Challenges and opportunities in the development of combination immunotherapy with OX40 agonists | |
| EP3976193A1 (en) | Dosing of bispecific t cell engager |